These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6146342)

  • 41. Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.
    Sotaniemi EA; Anttila M; Pelkonen RO; Järvensivu P; Sundquist H
    Clin Pharmacol Ther; 1979 Aug; 26(2):153-61. PubMed ID: 455885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clofibrate and enzymatic induction in man.
    Houin G; Tillement JP
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):150-4. PubMed ID: 649234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymorphic metabolism of beta-adrenoceptor antagonists.
    Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.
    Warrington SJ; Holt D; Johnston A; Fitzsimons TJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):37S-44S. PubMed ID: 6146339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.
    Perucca E; Hedges A; Makki KA; Richens A
    Br J Clin Pharmacol; 1980 Nov; 10(5):491-7. PubMed ID: 7437261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Balanced pharmacokinetics and metabolism of bisoprolol.
    Leopold G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S16-20. PubMed ID: 2439789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.
    Bell JM; Russell CJ; Nelson JK; Kelly JG; McDevitt DG
    Br J Clin Pharmacol; 1977 Feb; 4(1):79-82. PubMed ID: 14661
    [No Abstract]   [Full Text] [Related]  

  • 49. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.
    Miguet JP; Mavier P; Soussy CJ; Dhumeaux D
    Gastroenterology; 1977 May; 72(5 Pt 1):924-6. PubMed ID: 849823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of propranolol isomers and their relationships with beta adrenoceptor blocking activity in rabbits administered with dl-propranolol.
    Kawashima K; Ishikawa H
    J Pharmacol Exp Ther; 1980 Jun; 213(3):628-31. PubMed ID: 6110769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Interactions between phenprocoumon (Marcumar) and drug-catabolizing, enzyme system-inducing pharmaceutic agents].
    Heni N; Völger R; Glogner P
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1579-82. PubMed ID: 347786
    [No Abstract]   [Full Text] [Related]  

  • 52. Beta-adrenoceptor blocker pharmacokinetics and the oral contraceptive pill.
    Kendall MJ; Jack DB; Quarterman CP; Smith SR; Zaman R
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):87S-89S. PubMed ID: 6146344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enzyme induction and renal function in man.
    Ohnhaus EE; Martin J; Kinser J; Colombo JP
    Br J Clin Pharmacol; 1977 Feb; 4(1):33-7. PubMed ID: 843422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.
    Liu XG; Narang PK; Li RC
    Eur J Drug Metab Pharmacokinet; 2001; 26(4):209-13. PubMed ID: 11808861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
    Vesell ES; Page JG
    J Clin Invest; 1969 Dec; 48(12):2202-9. PubMed ID: 5389794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medroxyprogesterone acetate does not induce antipyrine clearance and only weakly increases alpha 1-acid glycoprotein in beagle dogs.
    Abramson FP; Moore CF; Hill MD
    Res Commun Chem Pathol Pharmacol; 1986 Jul; 53(1):65-78. PubMed ID: 2944196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.
    Jordö L; Attman PO; Aurell M; Johansson L; Johnsson G; Regårdh CG
    Clin Pharmacokinet; 1980; 5(2):169-80. PubMed ID: 6102500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced plasma binding of propranolol and oxprenolol and induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the dog.
    Belpaire FM; Rosseel MT; De Rick A
    Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):303-4. PubMed ID: 7181586
    [No Abstract]   [Full Text] [Related]  

  • 59. Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.
    Teunissen MW; Bakker W; Meerburg-Van der Torren JE; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):701-6. PubMed ID: 6508979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents.
    Richter E; Breimer DD; Zilly W
    Eur J Clin Pharmacol; 1980; 17(3):197-202. PubMed ID: 7363932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.